981 results on '"Seghatchian, Jerard"'
Search Results
52. Back to basics on assessment of extracellular vesicle activity states, using modern captured based assays, combined with innovative IFC and proteomics, that might become tomorrow’s realities
53. Current debate on pathogen inactivation of platelet concentrates – To use or not to use?
54. Exploratory spotlights on the proteome of extracellular vesicles in red blood cell units prepared by the same donors revealed that leukoreduction may matter for the quality and safety of transfusion therapy: Back to basics for research topics that might begin tomorrow’s realities
55. What’s happening CAR T cell immunotherapy
56. The relationship of anti-HPA-1a amount to severity of neonatal alloimmune thrombocytopenia – Where does it stand?
57. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount
58. Polycythaemia vera: molecular genetics, diagnostics and therapeutics
59. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic
60. What's happening editorial commentary: Immunological impacts CD71+RBC subpopoulation present in stored blood and validation of a new irradiation system for off-line EPC
61. The six questions of pathogen reduction technology: An overview of current opinions
62. Updates on pathogen inactivation of plasma using Theraflex methylene blue system
63. Passive immunotherapy, for the management of over 65 ages against the evolving fast spreading SARS CoV-2 variants infection
64. Facts and challenges on global deployment of vaccines for the Immunotherapy of the evolving SARS Cov-2 variants, from the UK perspectives
65. On the Quest for In Vitro Platelet Production by Re-Tailoring the Concepts of Megakaryocyte Differentiation
66. An introductory commentary on the use of artificial intelligence, machine learning and TQM, as novel computational tools in big data patterns or procedural analysis, in transfusion medicine
67. An overview of unresolved inherent problems associated with red cell transfusion and potential use of artificial oxygen carriers and ECO-RBC: Current status/future trends
68. Updates on Stem Cell Therapy in Transfusion Medicine, New Approaches to RBC Substitution Therapy, the Use of IFC for the Assessment of Extracellular- Derived Vesicles/Exosomes
69. In vitro mass production of reproducible human cells destined for substitution therapy: Challenges for development of functional materials for what we need most in transfusion!
70. The secrets of human stem cell-derived transfusable RBC for targeted large-scale production and clinical applications: A fresh look into what we need most and lessons to be learned
71. Monitoring plasma levels of factor Xa inhibitors: how, why and when?
72. Pathogen-reduction systems for blood components: The current position and future trends
73. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends
74. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience
75. International forum – The “6 Pillars” of best practice in apheresis technologies: Introductory remarks
76. Platelet storage lesion: An update on the impact of various leukoreduction processes on the biological response modifiers
77. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID‐19 infected patients
78. Shedding light on the quality profiles of stem cells, whole blood and the supply of cryopreserved blood-derived bioproducts
79. Opportunities for standardization of cold stored, low-titre group O WB products
80. Emergency Supply Policy of Cryopreserved RBC and PLT: The Czech Republic Concept
81. Insights on Policies for Stem Cell and Frozen Blood Bioproducts
82. The state of plasma fractionation in technologically disadvantaged countries and current perspectives on the classification and applications of platelet-derived bio-products used in regenerative medicine
83. An open invitation on: Pathogen safety standard of human platelet lysate for regenerative medicine; beneficial use of PRP in treatment of musculoskeletal pathologies and newer challenges on vitamin B12 deficiency and metabolism- mediated thrombotic microangiopathy
84. An open call out on continual quality/safety improvement strategies in transfusion science and medicine
85. Revisiting the activated protein C-protein S-thrombomodulin ternary pathway: Impact of new understanding on its laboratory investigation
86. Editorial
87. Reflections on current status of blood transfusion transplant viral safety in UK/Europe and on novel strategies for enhancing donors/recipients healthcare in promising era of advanced cell therapy/regenerative medicine
88. What’s happening: An overview of potential adverse reactions associated with apheresis technology
89. What’s happening? The expanding role of apheresis platelet support in neonatal alloimmune thrombocytopenia: Current status and future trends
90. The influence of methylene blue light treatment and methylene blue removal filter on fibrinogen activity states and fibrin polymerisation indices
91. Red cell storage lesion: The potential impact of storage-induced CD47 decline on immunomodulation and the survival of leucofiltered red cells
92. The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components
93. Editorial: Time to explore the missing links: from activated platelets and platelet extracellular vesicles in SARS-CoV-2 infection, through heterogeneity in the host physiological, immuno-inflammatory and haemostatic responses to mRNA-based vaccine or infection induced polyclonal neutralizing antibodies and passive immunity
94. Bacterial contamination in blood components and preventative strategies: an overview
95. What is happening? Are the current acceptance criteria for therapeutic plasma adequate?
96. Variables determining blockage of WBC-depleting filters by Hb sickle cell trait donations
97. Editorial: An all-round appraisal of the latest viewpoints on “Acute Thrombotic Coagulability” and an update on the “inflammation-conditioned” profiles of platelets in sepsis patients
98. Universal leucodepletion: an overview of some unresolved issues and the highlights of lessons learned
99. Elevated FXIIIA and serine proteases upon filtration of platelet concentrate on negatively charged filters: comparison with other established haemostatic markers of platelet activation and storage lesion
100. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.